Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with M. bovis BCG or Other Therapies

Biomedicines, Год журнала: 2025, Номер 13(1), С. 156 - 156

Опубликована: Янв. 10, 2025

Background: Immunotherapy is gaining great relevance in both non-muscle-invasive bladder cancer (NMIBC), with the use of bacille Calmette-Guerin (BCG), and muscle-invasive BC (MIBC) anti-checkpoint therapies blocking PD-1/PD-L1, CTLA-4/CD80-CD86, and, more recently, NKG2A/HLA-E interactions. Biomarkers are necessary to optimize these therapies. Methods: We evaluated killer-cell immunoglobulin-like receptors (KIRs) HLA-I genotyping expression NK cell circulating T lymphocytes at diagnosis 325 consecutive patients (151 treated BCG 174 other therapies), as well 648 cancers 973 healthy donors controls. The proliferation production cytokines cytotoxicity were peripheral blood mononuclear cells, stimulated vitro anti-CD3/CD28 or BCG, from selected based on HLA-B -21M/T dimorphism (NKG2A ligands). Results: genotype showed opposing results MM genotype, compared MT TT, was associated a longer 75th-percentile overall survival (not reached vs. 68.0 ± 13.7 52.0 8.3 months, p = 0.034) but shorter (8.0 2.4 21.0 3.4 19.0 4.9 0.131) treatments. an independent predictive parameter progression-free (HR 2.08, 0.01) OS 2.059, 0.039) together age tumor histopathologic characteristics. higher counts CD56bright, fewer KIR2DL1/L2+ lower NKG2A expression, not differential functionality. Conclusions: independently patient outcomes can help new immunotherapies patients.

Язык: Английский

---

PD-L1 expression in prostate cancer and Gleason Grade Group: is there any relationship? Findings from a multi-institutional cohort.

Pathology - Research and Practice, Год журнала: 2025, Номер unknown, С. 155916 - 155916

Опубликована: Март 1, 2025

Язык: Английский

---

Efficacy and safety of RC48 in combination with PD-1 inhibitors for the treatment of locally advanced or metastatic urothelial carcinoma: a single-center, real-world study

Discover Oncology, Год журнала: 2025, Номер 16(1)

Опубликована: Апрель 18, 2025

This study aims to assess the efficacy and safety of RC48 in combination with PD-1 inhibitors for patients diagnosed locally advanced or metastatic urothelial carcinoma (mUC). A retrospective analysis was performed on clinical data from 53 bladder cancer, who were treated at First Affiliated Hospital Bengbu Medical College between January 2023 December 2023. The cohort stratified into two groups: combined immunotherapy group (RC48 + PD-1, n = 27) conventional chemotherapy (gemcitabine cisplatin regimen, GP, 26). demonstrated significantly higher objective response rates (ORR) median progression-free survival (PFS) compared (P < 0.05). Notably, incidence grade 3 adverse events elevated cohort, predominantly due hematologic toxicities, no treatment-related fatalities reported. In contrast, primarily experienced immune-related events, without any incidents effects deaths. exhibits promising antitumor activity a manageable profile UC.

Язык: Английский

---

A Novel Approach for Bladder Cancer Treatment: Nanoparticles as a Drug Delivery System

International Journal of Nanomedicine, Год журнала: 2024, Номер Volume 19, С. 13461 - 13483

Опубликована: Дек. 1, 2024

Bladder cancer represents one of the most prevalent malignant neoplasms urinary tract. In Asian context, it eighth common in males. 2022, there were approximately 613,791 individuals diagnosed with bladder worldwide. Despite availability efficacious treatments for two principal forms cancer, namely non-invasive and invasive high incidence recurrence following treatment suboptimal outcomes observed patients high-grade advanced disease represent significant concerns management at this juncture. Nanoparticles have gained attention their excellent properties, including stable physical a porous structure that can be loaded variety substances, so on. The in-depth research on nanoparticles has led to emergence as new class combination therapy, due advantageous properties. These include extension drug release window, enhancement bioavailability, improvement targeting ability, reduction local systemic toxicity, simultaneous delivery multiple drugs therapy. As result, become novel agent system. advent provided impetus development non-surgical chemotherapy, immunotherapy, gene therapy phototherapy. unique properties facilitated diverse therapeutic modalities, enhancing overall efficacy. This review examines recent advancements use treatments, encompassing aspects such delivery, efficacy, associated toxicity nanoparticles, well challenges encountered clinical applications.

Язык: Английский

---

Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in bladder urothelial carcinoma

Discover Oncology, Год журнала: 2024, Номер 15(1)

Опубликована: Ноя. 6, 2024

The biological significance of cancer-associated fibroblasts (CAFs) in bladder urothelial carcinoma (BUC) warrants further investigation. There is an urgent need to explore the predictive utility CAF-related genes for prognosis BUC. transcriptome and clinical data 407 BUC patients Cancer Genome Atlas (TCGA) database were analyzed a prognostic model was established. A total 476 cases from E-MTAB-4321 used validation. risk constructed utilizing through LASSO Cox regression, investigating its association with prognosis, gene mutations, immune cell infiltration, drug sensitivity We identified five (EGFL6, NRSN2, SEMA3D, TM4SF1 TPST1) both TCGA datasets, established using regression. high-risk group showed significant correlation poor survival. Furthermore, low-risk exhibited higher tumor mutational burden lower levels this holds promise guiding selection patients. These findings underscore pivotal role prediction Clinical decision-making tailored therapeutics stand benefit these results, providing valuable reference future research endeavors.

Язык: Английский

---

Use of 3′ Rapid Amplification of cDNA Ends (3′ RACE)-Based Targeted RNA Sequencing for Profiling of Druggable Genetic Alterations in Urothelial Carcinomas

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(22), С. 12126 - 12126

Опубликована: Ноя. 12, 2024

Targeted treatment of advanced or metastatic urothelial carcinomas (UCs) requires the identification druggable mutations. This study describes development a 3' Rapid Amplification cDNA Ends (3' RACE)-based targeted RNA sequencing panel which accounts for status all genes relevant to UC treatment, namely,

Язык: Английский

---